HDAC9 and acute myeloid leukemia: Such patients may instead receive low-toxicity AML-stabilizing treatment, e.g., a histone deacetylase (HDAC) inhibitor combined with all-trans retinoic acid (ATRA) and low-dose cytotoxic drugs [9].